All In MedTech

Device Trial Radar · NCT04187599

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D) Rigid Gas Permeable Contact Lenses for Corneal Refractive Therapy for Temporary Myopic Refractive Power Reduction

Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Aug 29, 2019

Primary completion

Nov 30, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
CooperVision International Limited (CVIL)Not on our public-company list
Sponsor type
Industry
Collaborators
TigerMed
First posted
Dec 5, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 8 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this post market clinical study is to evaluate the effectiveness and safety of the Paragon CRT®100 Contact Lens.

Conditions

  • Myopia

Interventions

  • Paragon CRT®100 Contact LensDevice

    Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. product effectivenessTime frame: 1 month
  2. uncorrected visual acuityTime frame: At baseline
  3. uncorrected visual acuityTime frame: 1 day

25 more outcomes with a free account

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Changsha Aier Eye Hospital

    Shanghai, China · Recruiting

  • Eye & ENT Hospital of Fudan University

    Shanghai, China · Recruiting

  • Tianjin Eye Hospital

    Tianjin, China · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.